TScan Therapeutics
TCRX
26 hedge funds and large institutions have $29M invested in TScan Therapeutics in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
8% more funds holding
Funds holding: 24 → 26 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
1.03% less ownership
Funds ownership: 51.26% → 50.23% (-1%)
54% less capital inflows, than outflows
Capital inflows: $477K | Capital outflows: $1.05M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$218K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$103K |
| 3 |
Privium Fund Management (UK)
London,
United Kingdom
|
+$51.8K |
| 4 |
Cannell Capital
Alta,
Wyoming
|
+$36.1K |
| 5 |
Prudential Financial
Newark,
New Jersey
|
+$36K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tang Capital Management
San Diego,
California
|
-$622K |
| 2 |
Woodline Partners
San Francisco,
California
|
-$215K |
| 3 |
NM
Newtyn Management
New York
|
-$159K |
| 4 |
Jane Street
New York
|
-$32K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$9.8K |
TCRX Hedge Fund Activity: Q3 2022 in Review
26 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q3 2022, worth a combined $29M — down 4.7% from $30.4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new TCRX positions and 1 closed out — a net gain of 2 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $218K. The largest seller was Tang Capital Management, cutting an estimated $622K.
- 26 institutional investors held TScan Therapeutics (TCRX) as of Q3 2022, up from 24 in Q2 2022.
- Funds reported $29M of TScan Therapeutics stock for Q3 2022, down 4.7% quarter-over-quarter.
- 3 funds opened new TScan Therapeutics positions in Q3 2022 and 1 closed out, a net change of +2 holders.
- The largest TScan Therapeutics buyer in Q3 2022 was Geode Capital Management, an estimated $218K added.
- The largest TScan Therapeutics seller in Q3 2022 was Tang Capital Management, an estimated $622K sold.
Based on aggregated 13F filings for Q3 2022.